Established in 2011, Hepatera is engaged in research on hepatitis B and D. In December of the same year the company became one of the residents of Skolkovo. At the end of the year, the drug for hepatitis D was registered. The innovative project was developed with the support of a group of scientists who had unique research methods. This allowed the latter to study the whole process of infection when the virus penetrates into the hepatocyte. The mechanism of the drug is designed in such a way that it prevents viral particles from getting inside the cell, thus preventing the spread of infection.

The potential of the drug can hardly be overestimated: every year about fifty million cases of hepatitis infection are registered in the world, and about two million people then die of liver disease. The essence of Hepater's innovation lies in Mycrludex B - behind this name lies a chemically synthesized chain of 47 amino acids. The company plans to continue searching for and bringing to the market medicinal products for liver diseases.

The Hepatera team is made up of exclusively highly qualified specialists. They are people who have more than one year of experience in clinical research and project management. These people have experience working in international pharmaceutical companies and research centers. In turn, the drug itself was created in cooperation with German colleagues from the Hanover Medical University. Thanks to such staff and professional alliances, as well as support from a number of organizations, hepatitis can really stop being a sentence in the near future.